Efficacy and Safety of SIL-8301 for Control of Hemolysis in a Uniform Sickle Cell Disease Endotype

NCT07282210 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

105

Enrollment

INDUSTRY

Sponsor class

Conditions

Sickle Cell Disease
Sickle Cell Anaemia
Sickle Cell Anemia

Interventions

DRUG: Senicapoc
DRUG: Placebo

Sponsor

Biossil Inc.